2637 — Fujian Haixi Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$12.73bn
- HK$11.18bn
- CNY582.36m
Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment
Brief: Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
Brief: Fujian Haixi Pharmaceuticals Elects Chen Tingze As Executive Director
Brief: Fujian Haixi Pharmaceuticals Nominates Chen Tingze As Candidate For Executive Director
Brief: Fujian Haixi Pharmaceuticals Discloses Final Offer Price HK$86.40 Per H Share Under Global Offering